News >

UCSF Expert Highlights Progress in Lymphoma Landscape

Brandon Scalea
Published: Monday, Oct 29, 2018

Lawrence D. Kaplan, MD

Lawrence D. Kaplan, MD

Several treatment questions remain following data from recent clinical trials in Hodgkin lymphoma, mantle cell lymphoma (MCL), and follicular lymphoma (FL), explained Lawrence D. Kaplan, MD.

According to findings from the phase III ECHELON-1 trial, brentuximab vedotin (Adcetris) combined with doxorubicin, vinblastine, and dacarbazine (A+AVD) has shown significant activity in patients with advanced Hodgkin lymphoma.

The initial results of the global study indicated a 5.1% benefit with A+AVD in 2-year modified progression-free survival (mPFS) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD). A subgroup analysis of the North American population revealed an absolute difference of 10.6% in mPFS per independent review facility and an 11.7% difference in PFS per investigator review at 2 years.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
The Patient and Provider Connection™: Effective Communication to Optimize the Diagnosis and Management of Irritable Bowel Syndrome and Chronic Idiopathic ConstipationOct 31, 20191.0
Publication Bottom Border
Border Publication
x